About: The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge
Creator	Sant, Andrea Weilhammer, Dina Rasley, Amy Alam, Shabnam Blanchette, Craig Corzett, Michele Dunkle, Alexis Fischer, Nicholas Ghanekar, Smita Loots, Gabriela Lychak, Cheri Ruitenberg, Joyce Thomas, Cynthia
Source	Elsevier; Medline; PMC
abstract	Abstract Recent studies have demonstrated that therapies targeting the innate immune system have the potential to provide transient, non-specific protection from a variety of infectious organisms; however, the potential of enhancing the efficacy of such treatments using nano-scale delivery platforms requires more in depth evaluation. As such, we employed a nanolipoprotein (NLP) platform to enhance the efficacy of innate immune agonists. Here, we demonstrate that the synthetic Toll-like receptor (TLR) agonists monophosphoryl lipid A (MPLA) and CpG oligodeoxynucleotides (CpG) can be readily incorporated into NLPs. Conjugation of MPLA and CpG to NLPs (MPLA:NLP and CpG:NLP, respectively) significantly enhanced their immunostimulatory profiles both in vitro and in vivo compared to administration of agonists alone, as evidenced by significant increases in cytokine production, cell surface expression of activation markers, and upregulation of immunoregulatory genes. Importantly, enhancement of cytokine production by agonist conjugation to NLPs was also observed in primary human dendritic cells. Furthermore, BALB/c mice pretreated with CpG:NLP constructs survived a lethal influenza challenge whereas pretreatment with CpG alone had no effect on survival.
has issue date	2013-12-31(xsd:dateTime)
bibo:doi	10.1016/j.biomaterials.2013.09.038
bibo:pmid	24075406
has license	els-covid
sha1sum (hex)	49ccae82e0af8758639ff75efb9a07a2553b6e63
schema:url	https://doi.org/10.1016/j.biomaterials.2013.09.038
resource representing a document's title	The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge
has PubMed Central identifier	PMC7172747
has PubMed identifier	24075406
schema:publication	Biomaterials
resource representing a document's body	covid:49ccae82e0af8758639ff75efb9a07a2553b6e63#body_text
is schema:about of	named entity 'studies' named entity 'demonstrated' named entity 'CpG' named entity 'platform' named entity 'expression' named entity 'evaluation' named entity 'agonists' named entity 'SYNTHETIC' named entity 'SIGNIFICANT' named entity 'MICE' named entity 'USING' named entity 'IMMUNE' named entity 'MPLA' named entity 'MPLA' named entity 'enhancement' named entity 'employed' named entity 'CpG' named entity 'innate immune system' named entity 'innate immune' named entity 'upregulation' named entity 'cytokine' named entity 'immunoregulatory' named entity 'influenza' named entity 'nano-scale' named entity 'dendritic cells' named entity 'TLR' named entity 'CpG' named entity 'agonist' named entity 'influenza' named entity 'observed' named entity 'acetonitrile' named entity 'fluorescence' named entity 'solubilized' named entity 'emerging pathogens' named entity 'MPLA' named entity 'CpG' named entity 'TNFa' named entity 'lysosomes' named entity 'murine' named entity 'fluorescence' named entity 'CpG' named entity 'serum' named entity 'serum' named entity 'retention time' named entity 'synergistic effect' named entity 'TLR' named entity '13.5' named entity 'CpG' named entity 'FlowJo' named entity 'spleens' named entity 'SARS' named entity 'cytokine secretion' named entity 'agonist' named entity 'CpG' named entity 'Gaithersburg' named entity 'innate immune responses' named entity 'influenza' named entity 'high-performance liquid chromatography' named entity 'inflammatory' named entity 'agonists' named entity 'macrophages' named entity 'long-term' named entity 'molar ratio' named entity 'protein' named entity 'TLR4' named entity 'CpG' named entity 'inflammasome' named entity 'fluorescence' named entity 'Toll-like receptors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software